BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

NCT03576378

PHASE1|PHASE2INTERVENTIONAL

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

41 participants

Started 2018-08-08 · Completed 2024-10-30

Status: Active Not Recruiting (as of 12-23-2025)

Conditions

Hodgkin Lymphoma

Interventions

DRUG: BrentuximabVedotin (BV)

Linked Papers (from SciSciNet-V2)

Total Papers18

Background

1

Result

0

Derived

0

Unknown

17

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

The purpose of the phase Ib of the study is to identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM and to assess the toxicity of the combination of BV with EPEM. In the phase II efficacy will be evaluated.Besides, progression-free survival (PFS), event-free survival (EFS), overall survival (OS), the duration of response, the overall response rate (ORR) based on best response will be evaluated

Sort by:

Background Papers2

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

1,429 citations

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

1,429 citations

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers17

Optimal two-stage designs for phase II clinical trials

3,494 citations

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

1,307 citations

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics

Hodgkin lymphoma in older patients: an uncommon disease in need of study.

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)

Hodgkin lymphoma in the elderly: A clinical review of treatment and outcome, past, present and future

Hodgkin's disease in the elderly: current status and future directions

The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma